Novartis generated $40 billion in innovative medicine sales, says CEO

Novartis and Glaxo Deal Reshapes Pharma Industry

Novartis CEO: We expect our six key drugs to grow ahead of analyst expectations

Novartis CEO Vas Narasimhan: Our medicines are starting to take market share and deliver on promises

AstraZeneca Stock vs Novartis Stock Comparison For Investing Different Option and Which One is Best

Novartis Financial Results Q1 2021

Pfizer vs Eli Lilly And Co vs Novartis stock analysis | Best pharma stock to BUY | PFE LLY NVS

Novartis CEO on the challenges of drugs coming off patent

Novartis: The making of a pharma giant

Big pharma: GSK beats forecasts, but Novartis lags

Turnill Likes Roche, Novartis, Schneider

Stocks to Watch in Europe: GSK, Novartis, Novo Nordisk, BBVA, Entain

Have an Employee Stock Purchase Plan? Don't Make This Mistake.

Novartis CEO Vasant Narasimhan on building trust with society

Novartis CEO: Nations pulling back on health care spending ‘has long-term consequences'

Novartis - Hot or Not

Novartis CEO: Expect continued growth in 2023

Joe Jimenez, CEO of Novartis at Berkeley-Haas

Job Curtis: why I sold Microsoft, and a sector to watch

Novartis' CEO Says Getting Momentum Back in Alcon Unit